Polypeptides

A technology for combining fragments and antigens, applied in the field of polypeptides, which can solve the problems of inability to mediate Fc effector functions, poor stability of single-chain fragments, etc.

Pending Publication Date: 2021-10-01
ALLIGATOR BIOSCI
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Fragment-based formats lacking the Fc portion have limited half-life and cannot mediate Fc effector functions
Formats with single-chain fragments (scFv) may be less stable

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polypeptides
  • Polypeptides
  • Polypeptides

Examples

Experimental program
Comparison scheme
Effect test

example 1

[1765] Example 1 – Generation and Manufacturability Evaluation of 20 Variants in an IgG-Fab Architecture

[1766] Materials and methods

[1767] design

[1768] A novel bispecific construct consisting of immunoglobulin (IgG) coupled to two Fab fragments via the C-terminal end of IgG was engineered into 20 different variants and the polypeptide linker between the N-terminal end of the Fab fragment light chain ( figure 1 ). Variants were generated using different combinations of mutations in the interface between VH-CH1 and VL-CK. The mutations used are well known in the public domain.

[1769] manufacturability

[1770] Bispecific antibodies were expressed in varying volumes of 600 μL–2 L using transient HEK293 and Expi293 HEK (Life Technologies) cultures according to the manufacturer's instructions. Using NGC system (BioRad), Bispecific proteins were purified from supernatants using the Avant system (GE Healthcare) or Predictor MabSelectSure 50 [mu]l 96-well plates (GE...

example 2

[1791] Example 2 - Stability and Solubility

[1792] Materials and methods

[1793] thermal stability

[1794] Melting temperatures were measured with a UNCle system (UNchained labs). Intrinsic fluorescence was measured during a linear ramp from 20°C to 95°C at a rate of 0.4°C / min. Data analysis was performed using UNcle Analysis software version 2.0 with default settings.

[1795] stability

[1796] Incubate samples in non-optimized buffer (PBS) at low (<1 mg / mL) or high (10 mg / mL) protein concentration at 2-8°C, room temperature, and 40°C for 1, 2, and 4 weeks or 1 1 week and 2 weeks, or 3 cycles of freeze-thaw. Protein degradation was measured by SE-HPLC, SDS-PAGE, A280, double ELISA and by visual inspection.

[1797] Shear Stress Stability

[1798] Duplicate samples were subjected to shear stress on a 96-well plate shaker MixMate (Eppendorf) with vigorous stirring at 2000 rpm for at least 30 minutes. Protein precipitates were removed by centrifugation at 3000 g for 1...

example 3

[1817] Example 3 – Combination Study

[1818] Materials and methods

[1819] double ELISA

[1820] Plates were coated with 0.5 μg / mL antigen (Ag1 or Ag2) in PBS overnight at 4°C. After washing in PBS / 0.05% Tween20 (PBST), plates were blocked with PBS / 2% BSA for at least 30 minutes at room temperature and then washed again. Serially diluted samples in PBS / 0.5% BSA were then added and allowed to bind for at least 1 hour at room temperature. After washing, plates were incubated with 0.5 μg / mL biotinylated Ag1 or Ag2 (one of the antigens not used for coating) for at least 1 hour at room temperature. Double-complexed bsAbs with Ag1 and Ag2 were detected with HRP-labeled streptavidin. SuperSignal Pico Luminescent was used as the substrate, and the luminescent signal was measured using Fluostar Optima.

[1821] Octet

[1822] Kinetic measurements were performed using the Octet RED96 platform (ForteBIo). Biotinylated or Fc-labeled antigens were coupled to streptavidin or amine-...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides bispecific antibodies of an antibody format, and which comprise one or more Fab fragments and an immunoglobulin molecule. The invention further provides compositions of said bispecific antibodies, as well as methods and uses of the same. The invention further provides a method of generating bispecific antibodies of the format.

Description

technical field [0001] The present invention relates to bispecific antibodies with a novel structural format, specific for two target antigens, and comprising immunoglobulins and Fabs. In the bispecific antibody, the Fab is appended by the light chain of the Fab to the C-terminal end of the heavy chain of the immunoglobulin. The invention also provides a polypeptide comprising an antigen-binding fragment having a specific mutation that promotes association of the heavy chain with the light chain. Background technique [0002] Cancer is the leading cause of premature death in developed countries. Immunotherapy for cancer aims to generate an effective immune response against tumor cells. This can be achieved, for example, by breaking tolerance to tumor antigens, enhancing antitumor immune responses, and stimulating local cytokine responses at tumor sites. The key effector cells for durable antitumor immune responses are activated tumor-specific effector T cells. Efficient ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28C07K16/30A61P35/00A61K39/00C07K16/32C07K16/46
CPCC07K16/468C07K2317/55C07K2317/94A61K2039/505C07K16/2878C07K16/30C07K2317/31C07K2317/75C07K2317/77C07K2317/92A61P35/00C07K2317/64C07K2317/522C07K2317/567C07K2317/35C07K2317/21C07K2317/41
Inventor A·萨尔L·冯尚茨A·尼尔森B·尼西加J·彼得松M·莱温
Owner ALLIGATOR BIOSCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap